Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SOLESENCE, INC.NANX · Entity 7041 | VP Human Resources & IT | May 22, 2019 | May 30, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SOLESENCE, INC.
Report date May 22, 2019 · Filed May 30, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.51 · Expires 2029-05-22 | Direct | 16,500 |
Reported balance
After 2019-05-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-05-22 · Grant · Acquired 16,500 · Balance 16,500 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2020-05-03 | Direct | 27,000 |
Reported balance
Holding disclosure · report date 2019-05-22 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 27,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2021-05-02 | Direct | 31,000 |
Reported balance
Holding disclosure · report date 2019-05-22 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 31,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2022-08-07 | Direct | 41,000 |
Reported balance
Holding disclosure · report date 2019-05-22 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 41,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2023-02-14 | Direct | 39,000 |
Reported balance
Holding disclosure · report date 2019-05-22 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 39,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.52 · Expires 2024-02-13 | Direct | 40,000 |
Reported balance
Holding disclosure · report date 2019-05-22 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 40,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.44 · Expires 2025-02-18 | Direct | 36,000 |
Reported balance
Holding disclosure · report date 2019-05-22 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 36,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2026-02-23 | Direct | 31,500 |
Reported balance
Holding disclosure · report date 2019-05-22 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 31,500 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2027-02-21 | Direct | 36,000 |
Reported balance
Holding disclosure · report date 2019-05-22 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 36,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2028-05-23 | Direct | 40,000 |
Reported balance
Holding disclosure · report date 2019-05-22 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 40,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common StockSEC Table I · non-derivative | Direct | 987 |
Reported balance
Holding disclosure · report date 2019-05-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 987 |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2019 Filed May 30, 2019 19:51 UTC | SOLESENCE, INC. NANX · Entity 7041 | GrantCommon Stock (right to purchase) · Derivative | 16,500 | $0.51 Strike: $0.51 | $8,415.00 |
DisclosureSEC source: 0001209191-19-033410 · doc4.xml · derivative · entry 11 Baldwin Nancy · CIK 0001446736 · VP Human Resources & IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2029-05-22 F1 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document |
| May 23, 2018 Filed May 24, 2018 22:35 UTC | SOLESENCE, INC. NANX · Entity 7041 | GrantCommon Stock (right to purchase) · Derivative | 40,000 | $0.82 Strike: $0.82 | $32,800.00 |
DisclosureSEC source: 0001209191-18-033148 · doc4.xml · derivative · entry 11 Baldwin Nancy · CIK 0001446736 · VP Human Resources & IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-05-23 F1 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 21:16 UTC | SOLESENCE, INC. NANX · Entity 7041 | GrantCommon Stock (right to purchase) · Derivative | 36,000 | $0.68 Strike: $0.68 | $24,480.00 |
DisclosureSEC source: 0001209191-17-013207 · doc4.xml · derivative · entry 12 Baldwin Nancy · CIK 0001446736 · VP Human Resources & IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2027-02-21 F1 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.